When used in combination with insulin or other medications that affect blood glucose, the risk of hypoglycemia may be increased
After just 46 hours at room temperature, a significant portion of the semaglutide may lose potency, meaning you receive less active medication than your dose level indicates
These effects are typically most noticeable when starting treatment or increasing doses and generally diminish over time as your body adjusts
Prior cardiovascular outcome trials of GLP-1RAs primarily involved patients with diabetes, making it difficult to separate cardiovascular benefits from glucose-lowering effects
What makes this significant is not just the initial loss, but the ability to sustain it over time, something most traditional diets fail to achieve
May 02, 2024, 08:01 ET First-and-only Health Canada-approved once-weekly medication for chronic weight management MISSISSAUGA, ON, May 2, 2024 /CNW/ - Novo Nordisk has announced that Wegovy (semaglutide injection) will be available for Canadians who meet the requirements in the Health Canada approved product monograph on May 6, 2024
